Pal Shripad N, Kofidis Theodoros
Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Expert Rev Cardiovasc Ther. 2013 Aug;11(8):1015-28. doi: 10.1586/14779072.2013.814867. Epub 2013 Aug 14.
Cardiovascular diseases remain the primary reason of premature death and contribute to a major percentage of global patient morbidity. Recent knowledge in the molecular mechanisms of myocardial complications have identified novel therapeutic targets along with the availability of vectors that offer the chance for designing gene therapy technique for protection and revival of the diseased heart functions. Gene transfer procedure into the myocardium is demonstrated through direct injection of plasmid DNA or through the coronary vasculature using the direct or indirect delivery of viral vectors. Direct DNA injection to the myocardium is reported to be of immense value in research studies that aims at understanding the activities of various elements in myocardium. It is also deemed vital for investigating the effect of the myocardial pathophysiology on expression of the foreign genes that are transferred. Gene therapies have been reported to heal cardiac pathologies such as myocardial ischemia, heart failure and inherited myopathies in several animal models. The results obtained from these animal studies have also encouraged a flurry of early clinical trials. This translational research has been triggered by an enhanced understanding of the biological mechanisms involved in tissue repair after ischemic injury. While safety concerns take utmost priority in these trials, several combinational therapies, various routes and dose of delivery are being tested before concrete optimization and complete potential of gene therapy is convincingly understood.
心血管疾病仍然是过早死亡的主要原因,并且在全球患者发病率中占很大比例。心肌并发症分子机制方面的最新知识已经确定了新的治疗靶点,同时也有了载体,这为设计用于保护和恢复患病心脏功能的基因治疗技术提供了机会。通过直接注射质粒DNA或将病毒载体直接或间接递送至冠状动脉血管系统,可实现将基因导入心肌的过程。据报道,直接将DNA注射到心肌中对于旨在了解心肌中各种元件活性的研究具有巨大价值。对于研究心肌病理生理学对所转移的外源基因表达的影响也至关重要。据报道,基因疗法已在多种动物模型中治愈了诸如心肌缺血、心力衰竭和遗传性肌病等心脏疾病。这些动物研究获得的结果也促使了一系列早期临床试验的开展。这种转化研究是由于对缺血性损伤后组织修复所涉及的生物学机制有了更深入的了解而引发的。虽然在这些试验中安全问题最为重要,但在令人信服地理解基因治疗的具体优化和全部潜力之前,正在测试几种联合疗法、不同的给药途径和剂量。